A multicenter, randomized, double-blinded, placebo-controlled phase III trial to evaluate efficacy and safety of picankibart in moderate-to-severe plaque psoriasis.
Yunlu Gao, Lanying Qin, Yumei Li, Yong Cui, Shifa Zhang, Lunfei Liu, Lihua Wang, Chao Ci, Jianyun Lu, Rixin Chen, Yanyan Feng, Shanshan Li, Chenghang Cai, Mingxia Chen, Han Han-Zhang, Yue Li, Lei Qian, Yuling Shi, CLEAR-1 Investigators
J Am Acad Dermatol 95(1) 87-94
摘要
摘要
BACKGROUND: The development of interleukin-23 inhibitors that offer sustained complete skin clearance with reduced-frequency dosing addresses a significant unmet clinical need in managing moderate-to-severe plaque psoriasis. OBJECTIVE: To evaluate the efficacy and safety of picankibart, an interleukin-23p19 inhibitor, in Chinese patients. METHODS: CLEAR-1 enrolled participants aged 18-75 years to randomly receive picankibart subcutaneously 200 mg at weeks 0/4/8/20/32/44, picankibart 200 mg at weeks 0/4/8 then 100 mg at weeks 20/32/44; or placebo at weeks 0/4/8 then picankibart 200 mg at weeks 16/20/24/32/44. The co-primary endpoints were ≥90% improvement in psoriasis area and severity index and static physician's global assessment clear/almost clear status (0/1) at week 16. RESULTS: In picankibart 200 mg group, 80.3% achieved ≥90% improvement in psoriasis area and severity index and 93.5% achieved static physician's global assessment 0/1 at week 16 vs 2.0% and 13.1%, respectively with placebo. All key secondary endpoints were significantly improved (all two-sided P < .0001 vs placebo). Efficacy was maintained through week 52 for both 100 mg and 200 mg doses, with no new safety signal observed. LIMITATIONS: Chinese only; no active comparator. CONCLUSION: Picankibart provided effective skin clearance in Chinese participants by week 16. A dosing regimen of every 12 weeks with either 100 mg or 200 mg maintained these clinical improvements through week 52.
KM 提取结果
0 个 Figure · 0 个 KM 面板